hVIVO PLC - London-based contract research organisation testing vaccines for infectious and respiratory diseases - Announces that certain directors intend to sell at least 14.0 million shares in total, at 28 pence each. Placing shares represent approximately 25% of the directors’ current shareholding. Selling shareholders include investment vehicles of Chair Cathal Friel, and his spouse Pamela Iyer.

Current stock price: 28.50 pence, down 2.9% in London on Wednesday

12-month change: up 39%

Copyright 2024 Alliance News Ltd. All Rights Reserved.